INTRODUCTION
============

Exposure of cells to ionizing radiation (IR) induces a broad spectrum of DNA damage including double-strand breaks, which are potentially lethal but can also lead to genomic instability, thereby increasing the cancer risk for the whole organism. Thus, a complex DNA damage response evolved to coordinate DNA repair, cell cycle regulation and eventually cell death for preventing those consequences. The key player of the radiation-induced damage response is the PI3-kinase-like kinase Ataxia-Telangiectasia Mutated (ATM), which is mutated in individuals suffering from the human syndrome Ataxia-telangiectasia (AT) ([@gks604-B1]). AT is a most severe neurodegenerative disorder that is associated with immunodeficiency, early cancer proneness and limited life span ([@gks604-B2]). Importantly, ATM is involved in double-strand break (DSB) recognition and activation of the appropriate signalling cascade, via phosphorylation of the histone component H2AX, recruitment and stabilization of the adaptor molecules MDC1 and 53BP1. ATM-mediated signalling contributes to the activation of downstream repair and cell cycle checkpoint proteins such as NBS1, SMC1, Chk2, p53 and BRCA1. Accordingly, ATM deficiency leads to abrogation of the cell cycle checkpoints G1/S, G2/M and intra-S ([@gks604-B3; @gks604-B4; @gks604-B5; @gks604-B6]), resulting in the most characteristic phenotype of radioresistant DNA synthesis (RDS), the failure to reduce the rate of DNA synthesis in response to IR ([@gks604-B7],[@gks604-B8]). RDS is caused when the Chk2-p53-p21 axis is not properly activated, and by a failure to delay origin firing or to interrupt ongoing replication after IR (the intra-S-phase checkpoint). Besides checkpoint activation, ATM is also implicated in DSB repair. Accordingly, loss of ATM precludes successful rejoining of a small fraction of DSBs, which is considered to be responsible for the greatly enhanced radiosensitivity of *AT* cells ([@gks604-B9; @gks604-B10; @gks604-B11; @gks604-B12]).

Recently, it was demonstrated that Artemis, the nuclease defective in RS-SCID ([@gks604-B13]), displays partly overlapping features with AT with respect to DSB repair. In contrast to ATM, Artemis appears not to be implicated in direct checkpoint activation ([@gks604-B5]). However, it was suggested that ATM/ATR-catalyzed phosphorylation of Artemis facilitates the recovery from G2-block through regulation of CyclinB/Cdk1 activation ([@gks604-B14],[@gks604-B15]). Biochemically, the Artemis protein is an exo- and endonuclease critically involved in the resolution of hairpin DNA structures ([@gks604-B16]), which are regular intermediates of V(D)J recombination. In addition, Artemis is capable of removing modified DNA termini such as radiation-induced phosphoglycolates ([@gks604-B17]). Although ATM and Artemis display defined enzymatical differences, both ATM- and Artemis-deficient cells share similar hypersensitivity to IR. Furthermore, epistatic and kinetic analyses of DSB repair revealed that ATM and Artemis might act in the same pathway, which includes the Mre11/Nbs1/Rad50 complex (MRN) and 53BP1 ([@gks604-B12],[@gks604-B18]). Recently, this pathway was linked to the repair process in heterochromatic regions of the genome ([@gks604-B18; @gks604-B19; @gks604-B20]). Defects in ATM and/or Artemis affect the slow component of DSB repair in G1/G0, which led to the conclusion that mainly non-homologous end joining (NHEJ) is concerned. However, solid evidence was provided that ATM is also involved in homologous recombination (HR) ([@gks604-B21; @gks604-B22; @gks604-B23; @gks604-B24; @gks604-B25]). Very recently, ATM, Artemis, BRCA2 and Rad51 were placed in the same HR pathway that is required for the repair of 10--15% of DSBs in the G2-phase ([@gks604-B20]). Relaxation of heterochromatic DNA, i.e. by Kap1 depletion, rendered ATM and Artemis dispensable for the repair, suggesting that ATM- and Artemis-dependent HR is responsible for DSB repair in heterochromatic regions in G2. Significant recombination activity also takes place during the S-phase to cope with directly induced DSBs as well as replication-associated DSBs. However, it is not known whether and how ATM and Artemis are involved in HR-directed repair during the S-phase.

Here, we investigated DSB repair, in particular HR, in the context of the cell cycle in *AT* and *Artemis* cells. In those cells, we found similar repair phenotypes in G2, confirming a common defect in the HR pathway. However, we observed strikingly different repair phenotypes during the S-phase. *Artemis* cells showed no HR defect during replication particularly with regards to Rad51 foci kinetics, indicating that the nuclease Artemis is not essential for HR in S-phase. *AT* cells, in contrast, displayed a pronounced HR defect with significant accumulation of Rad51 foci, which fail to decline later suggesting an initiated but incomplete recombination process during replication in the absence of ATM.

MATERIALS AND METHODS
=====================

Cells
-----

The human fibroblast cell lines (kindly provided by P.A. Jeggo) 1BR.3 (wild-type), AT1BR (ATM deficient), FO2-385 and CJ179 (Artemis deficient) were grown in alpha-medium (Gibco-Invitrogen, Karlsruhe, Germany) supplemented with 10% fetal calf serum (FCS). All of the utilized human fibroblast cell lines displayed a similar proliferation rate with population doubling times 26.5, 27.2, 24.4 and 27.8 h, respectively. The human cervical carcinoma cell lines HeLa and HeLa-pGC (containing the gene conversion substrate) were cultured in Dulbecco's modified Eagle medium (DMEM; Gibco-Invitrogen) supplemented with 10% FCS. CV-1, an African green monkey kidney cell line, was grown in DMEM supplemented with 5% FCS.

Small interfering RNA and inhibitors
------------------------------------

Rad51, Artemis, ATM and control (scrambled, CyclophilinB, GAPDH) small interfering RNA (siRNA) oligonucleotides were obtained from Dharmacon SMARTpool (Artemis: GUACGGAGCCAAAGUAUAA, GCACAACUAUGGAUAAAGU, UGAAUAAGCUAGACAUGUU, CACCAAAGCUUUUCAGUGA; ATM: GCAAAGCCCUAGUAACAUA, GGUGUGAUCUUCAGUAUAU, GAGAGGAGACAGCUUGUUA, GAUGGGAGGCCUAGGAUUU). ATR siRNA was obtained from MWG Biotech (ATR: AAGCCAAGACAAAUUCUGUGU). HiPerFect transfection reagent (Qiagen) was used for the knock down in HeLa. Cells were incubated with the siRNA complexes twice (first time with 25 nM, second time after 48 h with 50 nM). CV-1 cells were transfected using Roti Fect Plus (Roth) transfection reagent. ATM and Chk1 were chemically inhibited using 10 µM KU55933 (Biozol) and 0.1 µM UCN-01 (Sigma), respectively.

DSB-repair reporter assay for gene conversion
---------------------------------------------

To induce DSBs, HeLa cells containing the stably integrated reporter construct for gene conversion pGC ([@gks604-B26]) were transfected with the I-SceI expression vector pCMV3xnls-I-SceI (2 µg) using LipoFectamin2000 (Invitrogen) as transfection reagent. Seventy-two hours after transfection the cells were assessed for green fluorescence by flow cytometry (FACScan, BD Bioscience). Treatment with siRNA (50 nM) for protein depletion had been started 48 h prior to DSB induction. A second boost of siRNA was transfected together with the I-SceI expression plasmid.

Western blotting
----------------

Western blot analyses were performed with whole-cell extracts using the freeze and thaw method for lysis ([@gks604-B27]). Proteins were resolved by gradient sodium dodecyl sulfate--polyacrylamide gel electrophoresis (4--15%), transferred onto a polyvinyl difluoride (PVDF) membrane and probed with the following primary antibodies: anti-Artemis (Novus Biologicals), anti-ATM (Epitomics), anti-Rad51 (Abcam), anti-pChk2, anti-pCHk1, anti-Chk1 (Cell Signaling) and anti-β-actin (Sigma--Aldrich). Bound primary antibodies were visualized with horseradish peroxidase -conjugated anti-rabbit and anti-mouse antibodies (Amersham).

Immunofluorescent microscopy
----------------------------

Cells were grown on coverslips, fixed with 2% formaldehyde (Merck) in phosphate-buffered saline (PBS) for 10 min and washed with PBS three times. Fixed cells were permeabilized (5 min on ice) with 0.2% Triton X-100 (Serva) in 1% bovine serum albumin (BSA, PAA)-PBS and blocked with 3% BSA for 1 h. In addition to DNA staining with 4′,6-diamidin-2-phenylindol (DAPI), the respective proteins were visualized with anti-Rad51 (Abcam), anti-γ-H2AX (Cell Signaling), anti-Cenp-F (Lifespan Biosciences) and secondary anti-mouse AlexaFluor594 (Invitrogen) or anti-rabbit fluorescein (Amersham) antibodies. Slides were mounted in Vectashield mounting medium (Vector Laboratories). Fluorescent microscopy was performed using the Zeiss AxioObserver.Z1 microscope (objectives: EC PlnN 40×/0.75 DICII, resolution 0.44 µm; PlnN Apo 63×/1.4 Oil DICII, resolution 0.24 µm; EC PlnN 100×/1.3 Oil DICII, resolution 0.26 µm and filters: Zeiss 43, Zeiss 38, Zeiss 49). Semi-confocal images were obtained using the Zeiss Apotome, Zeiss AxioCam MRm and Zeiss AxioVision Software.

Cell cycle analysis
-------------------

For flow cytometry, cells were harvested and fixed with 80% ethanol (−20°C). The fixed cells were washed with PBS and DNA was stained with PI solution containing RNase A. Cell cycle distribution was monitored by flow cytometry (FACScan, BD Bioscience) and analyzed by the ModFit software (Verity Software House).

To monitor cell cycle distribution by fluorescence microscopy, cells were incubated with 5-ethynyl-2′-deoxyuridine (EdU, 1:2000; Click-iT Assay Kit, Invitrogen) for 24 h and then fixed and stained for EdU (following the manufacturer's protocol) and additionally for centromeric protein F (Cenp-F) and DNA (DAPI). Differentially stained sub-fractions of the entire cell population were enumerated by eye. DNA repair in irradiated S-phase cells was monitored by pulse-labeling the cells with EdU 30 min before irradiation and only EdU-positive cells were evaluated. Additional Cenp-F staining was performed to identify G2-phase cells. For evaluating cells in G2, progression of EdU-pulse labeled S-phase cells into G2 was blocked by 5 µM aphidicolin (Sigma--Aldrich). EdU-positive cells were now excluded from analysis, monitoring Cenp-F-positive and accordingly G2-phase cells only.

Colony formation assay
----------------------

For colony formation, cells were seeded and allowed to adhere before drug treatment or irradiation. The specific ATM inhibitor (10 µM KU55933) was added 30 min prior to irradiation (200 keV, 15 mA, additional 0.5 mm Cu filter at a dose rate of 0.8 Gy/min) and kept in the medium for 24 h. To temporarily block replication, cells were exposed to 5 µM aphidicolin for 5--6 h, commencing 30 min before IR. Cells were then incubated in drug-free medium for colony formation and stained with crystal violet. Colonies of 50 cells or more were counted manually and survival curves were derived from triplicates of at least three independent experiments.

Graphs and statistics
---------------------

If not stated otherwise, experiments were independently repeated at least three times. Data points represent the mean (±SEM) of all individual experiments.

Statistical analysis, data fitting and graphics were performed with the GraphPad Prism 5.0 program (GraphPad Software).

RESULTS
=======

*AT* and *Artemis* cells share hyper-radiosensitivity and repair defects but display important differences in the cell cycle response
-------------------------------------------------------------------------------------------------------------------------------------

The colony formation assay was applied to confirm hypersensitivity of ATM and Artemis-deficient human fibroblasts. As expected, radiation-induced cell death of *AT* and *Artemis* cells was largely enhanced when compared with normal wild-type (WT) cells. The degree of radiosensitivity was surprisingly similar ([Figure 1](#gks604-F1){ref-type="fig"}A), although ATM and Artemis proteins have widely divergent biochemical functions with respect to cell cycle regulation and DNA repair. Figure 1.Similarly enhanced radiosensitivity in *AT* and *Artemis* fibroblasts due to an enhanced number of residual DSBs. (**A**) Radiosensitivity of exponentially growing WT, *AT* and *Artemis* cells (FO2-385) was measured by colony formation after various X-ray doses. Error bars represent the SEM of three independent experiments. (**B**) Differential staining for G2-phase cells (Cenp-F-positive) 24 h after irradiation with 1 Gy in addition to detection of γH2AX foci. Bars, 10 µm. Quantification of residual γH2AX foci in (**C**) Cenp-F-negative G1-phase cells and (**D**) Cenp-F-positive G2-phase cells 24 h after IR (1 Gy). S-phase cells showing a strong pan-nuclear γH2AX signal were excluded from the analysis. The *AT* cell line AT1BR proved to be hyperploid (1.5-fold enhanced compared with WT and *Artemis* cells (data not shown)). Their foci number/nucleus was normalized to a diploid DNA content.

Cell cycle distribution 24 h after IR showed a significantly reduced fraction of S-phase cells in both WT and *Artemis* strains, indicating a sustained G1-arrest. In contrast, *AT* cells predominantly accumulated in the G2-phase ([Supplementary Figure 1A](http://nar.oxfordjournals.org/cgi/content/full/gks604/DC1)) although ATM is known to be required for the G2-checkpoint activation and maintenance ([@gks604-B4],[@gks604-B5],[@gks604-B28]). Since different repair pathways may apply, depending on the cell cycle phase, we determined the number of non-resolved γH2AX foci ([Figure 1](#gks604-F1){ref-type="fig"}B), which correspond to the number of unrepaired DSBs in either the G1- or the G2-phase of the cell cycle 24 h after IR. To distinguish between both phases, cells were additionally stained for the G2 marker Cenp-F*.* Separate analyses of G1- (only DAPI-positive, [Figure 1](#gks604-F1){ref-type="fig"}B and C) and G2-phase cells (in addition Cenp-F-positive, [Figure 1](#gks604-F1){ref-type="fig"}B and D) revealed for *AT* and *Artemis* cells in comparison to WT cells enhanced numbers of residual γH2AX foci in both cell cycle phases. *Artemis* cells showed 5.0 ± 0.2 foci/nucleus in the G1- and 10.8 ± 1.0 foci/nucleus in the G2-phase compatible with the 2-fold higher DNA content. In contrast, *AT* cells showed 4.1 ± 0.8 foci in the G1-phase and 12.1 ± 0.8 in the G2-phase, suggesting that additional foci are formed besides those expected from doubling the DNA content. Since *AT* cells but not *Artemis* cells continue DNA synthesis after IR, new DSBs may arise during the S-phase in *AT* cells.

To distinguish between cells that have passed replication from those that were immediately arrested in the respective cell cycle phases, cells were incubated with the thymidine analog EdU (S-phase) and additionally stained for Cenp-F (G2-phase) ([Supplementary Figure 1B](http://nar.oxfordjournals.org/cgi/content/full/gks604/DC1), ([@gks604-B20],[@gks604-B29],[@gks604-B30])). During the 24-h observation period following irradiation with 1 Gy, 11% of WT and 40% of *Artemi*s, cells failed to incorporate EdU and therefore did not pass through the S-phase, indicating a radiation-induced primary G1-arrest ([Supplementary Figure 1B](http://nar.oxfordjournals.org/cgi/content/full/gks604/DC1), Example (1) blue bars; at 2 Gy the respective numbers were 28 and 52%). In contrast, all *AT* cells were EdU positive, displaying their defect in the G1-checkpoint activation. The fraction of *AT* cells that were in addition Cenp-F-positive increased upon irradiation ([Supplementary Figure 1B](http://nar.oxfordjournals.org/cgi/content/full/gks604/DC1), Example (3), yellow bars), confirming the accumulation of *AT* cells in G2 ([Supplementary Figure 1A](http://nar.oxfordjournals.org/cgi/content/full/gks604/DC1)). Together these results demonstrate that after irradiation *AT* cells pass through replication and arrest in the following G2-phase, without being blocked in either G1- or S-phase.

*AT* and *Artemis* cells show distinct HR defects
-------------------------------------------------

The similar *AT* and *Artemis* repair phenotype was hitherto linked to deficient repair of a common subset of DSBs (10--15%) in both the G1- and 2-phase of the cell cycle ([@gks604-B5],[@gks604-B12]). We now observed a different amount of residual damage when the 24-h observation period included the S-phase, which may implicate HR of replication-associated damage to a yet unknown extent. This possibility was addressed by monitoring Rad51 focus formation as a marker of recombination activity 24 h after IR ([Figure 2](#gks604-F2){ref-type="fig"}). Differential staining showed discrete nuclear Rad51 foci only in Cenp-F and/or EdU-positive cells (S- and G2-phase, respectively, see below) but never in G1 or confluent G0 cells ([Figure 2](#gks604-F2){ref-type="fig"}A and [Supplementary Figure 4](http://nar.oxfordjournals.org/cgi/content/full/gks604/DC1)) confirming that recombination processes are restricted to both the S- and G2-phase of the cell cycle. Enumeration after 1 Gy revealed in *AT* cells on average 11.7 ± 1.1 Rad51 foci but only 5.7 ± 0.5 and 6.6 ± 0.5 in WT and FO2-385 *Artemis* cells, respectively. Importantly, in WT and *AT* cells Rad51 and γH2AX foci were frequently co-localized giving thus identical numbers while in FO2-385 *Artemis* cells 39% of residual γH2AX foci were not decorated with Rad51 ([Figure 2](#gks604-F2){ref-type="fig"}B and C). To confirm these results, we examined a second *Artemis*-deficient cell line, CJ179, which displayed essentially the same phenotype although on a slightly lower level ([Figure 2](#gks604-F2){ref-type="fig"}B and C). γH2AX foci are generally considered the equivalent of unrepaired DSBs while Rad51 foci represent an early step in HR, which involves recruitment and loading of this major recombinase onto single-stranded DNA (ssDNA) ([@gks604-B31]). However, persistent Rad51 foci can also indicate non-completed recombination processes. Thus, the lower number of Rad51 foci in *Artemis* (compared with γH2AX foci) as well as the enhanced amount of Rad51 foci in *AT* cells could reflect HR defects, perhaps affecting different steps in the recombination process, respectively. Figure 2.The number of Rad51 foci in G2 is elevated in *AT* but not in *Artemis* cells. (**A**) Differential staining for G2-phase cells (Cenp-F-positive) in addition to detection of Rad51. Rad51 foci were visible only in Cenp-F-positive G2-phase cells (left panel). Magnification revealed distinct Rad51 foci (yellow as merged from green and red). The right panel depicts the red channel only as recorded in black/white. (**B**) Cells were co-stained for γH2AX and Rad51, which showed that in *AT* cells all Rad51 foci co-localized with γH2AX but not in both *Artemis* cell lines. Shown are cells in G2. G1 cells did not stain for Rad51 and S-phase cells with hyperintense γH2AX signals were not considered. Bars, 10 µm. (**C**) Quantification of Rad51 and γH2AX foci 24 h after IR revealed identical numbers for both damage markers in WT and *AT* but not in both *Artemis* cell lines.

To quantify HR more directly, the pGC gene conversion reporter construct ([Figure 3](#gks604-F3){ref-type="fig"}A, ([@gks604-B26])) was stably integrated into HeLa cells. After DSB induction through expression of the I-SceI endonuclease, successful gene conversion led to green fluorescence in 1.9 ± 0.25% of the cells ([Supplementary Figure 3A](http://nar.oxfordjournals.org/cgi/content/full/gks604/DC1))*.* Next, we depleted Artemis and ATM by siRNA ([Figure 3](#gks604-F3){ref-type="fig"}B, [Supplementary Figure 2A--C](http://nar.oxfordjournals.org/cgi/content/full/gks604/DC1)). Artemis siRNA reduced the HR frequency significantly to 51 ± 6% compared with control siRNA ([Figure 3](#gks604-F3){ref-type="fig"}C). In contrast, ATM knock down diminished HR frequency to only 67 ± 5% of controls. Combining Artemis and ATM knock down only slightly enhanced the effect of Artemis siRNA alone ([Figure 3](#gks604-F3){ref-type="fig"}C, columns 2--4). Perhaps, the siRNA treatment retained residual ATM activity, because western blots confirmed efficient, but not complete depletion of the ATM protein ([Figure 3](#gks604-F3){ref-type="fig"}B). Figure 3.Reduced rate of gene conversion in the absence of ATM and Artemis. (**A**) Schematic structure of the GFP-based reporter construct for gene conversion (pGC). (**B**) Western blot of HeLa cells that have been treated with siRNA against ATM, Artemis and Rad51. siRNA anti-GAPDH or anti-CyclophyllinB were used as controls. (**C**) Gene conversion (GC) was determined after DSB induction using HeLa-pGC cells. Cells treated with control siRNA were transfected with the I-SceI expression vector and the fraction of GFP-positive cells was determined 72 h later by flow cytometry (control siRNA reduced GC from 1.9 to 1.4%) ([Supplementary Figure 3A](http://nar.oxfordjournals.org/cgi/content/full/gks604/DC1)) and expressed as 100% relative repair efficiency (lane 1). ATM, Artemis or combined siRNA pretreatment reduced this repair efficiency (lanes 2--4). Combination of siRNAs and ATM inhibitor (10 µM of KU55933) further reduced GC efficiency (lane 5--8). Combination of Artemis siRNA and ATM inhibition (lane 8) was significantly different from ATM inhibition alone (lane 5) (Mann--Whitney two-tailed *t-*test, *P* = 0.0381). Rad51 depletion completely abrogated GC (lanes 9--12). DMSO did not affect recombination in controls ([Supplementary Figure 3B](http://nar.oxfordjournals.org/cgi/content/full/gks604/DC1)). (**D**) Cell cycle distribution 36 h after transfection of the I-SceI expression vector did not show marked differences upon drug treatment.

The assumption was investigated by inhibiting ATM chemically using the inhibitor KU55933 ([Supplementary Figure 2D--F](http://nar.oxfordjournals.org/cgi/content/full/gks604/DC1), [Supplementary Figure 3B](http://nar.oxfordjournals.org/cgi/content/full/gks604/DC1)). Inhibition of ATM decreased the HR efficiency to 29 ± 4% ([Figure 3](#gks604-F3){ref-type="fig"}C, column 5) and this value could not be further reduced by additional ATM or control siRNA ([Figure 3](#gks604-F3){ref-type="fig"}C, columns 6--7), supporting previous findings that the KU55933-inhibitor completely abrogated ATM function ([@gks604-B20],[@gks604-B32]). However, combining Artemis depletion with ATM inhibition ([Figure 3](#gks604-F3){ref-type="fig"}C, column 8) further compromised HR capacity to 17 ± 3% of controls (*P* = 0.038). This additive effect suggests that both proteins exert essential but partly divergent functions in HR. For comparison, we depleted Rad51, which completely abrogated gene conversion ([Figure 3](#gks604-F3){ref-type="fig"}B and C, columns 9--12), confirming our previous observation ([@gks604-B26]). In parallel, the DNA content was monitored to exclude pure cell cycle-related effects through inhibition of ATM and Artemis ([Figure 3](#gks604-F3){ref-type="fig"}D). Together, these results indicate that in fact ∼80% of the gene conversion activity in this system depends on ATM and Artemis.

DSBs induced during the S-phase account for different Rad51 foci numbers in *AT* and *Artemis* cells
----------------------------------------------------------------------------------------------------

The moderate differences in gene conversion might not well match with the discrepancies of persistent Rad51 foci in *AT* and *Artemis* cells in G2 ([Figure 2](#gks604-F2){ref-type="fig"}C). To elucidate whether Rad51 foci form during the G2-phase, we excluded S-phase cells from analysis. To this end, cells were labeled with EdU for 30 min before irradiation and a subsequent addition of aphidicolin prevented S-phase cells from entering the G2-phase ([@gks604-B20]). Rad51 focus formation in G2 was monitored in EdU-negative/Cenp-F-positive cells. WT cells showed a steep increase and a subsequent decline of the Rad51 foci number likely due to repair by HR ([Figure 4](#gks604-F4){ref-type="fig"}A). Both *AT* and *Artemis* cells showed only a moderate increase and almost no decline of Rad51 foci with time, which confirms reduced capability of HR in both defective cell lines also observed previously ([@gks604-B20]). The increase of the foci number was remarkably delayed in *AT* cells. However, *AT* and *Artemis* as well as WT cells, being still in the G2-phase 6 h after IR, displayed identical numbers of Rad51 foci ([Figure 4](#gks604-F4){ref-type="fig"}A). Figure 4.HR during the S-phase is dependent on ATM but not Artemis. (**A**) WT, *AT* and FO2-385 cells were EdU pulse-labeled, irradiated with 1 Gy and further incubated with aphidicoline (+Aphi) (5 µM) to block the transition of S-phase cells into G2. Kinetics of Rad51 foci numbers were monitored in Cenp-F-positive and EdU-negative G2 cells for the time interval indicated. (**B**) WT, *AT* and the *Artemis* cell lines FO2-385, CJ179 were EdU pulse-labeled, irradiated (1 Gy) and kinetics of Rad51 foci were evaluated in EdU-positive cells. (**C**) Upon ATM inhibition (10 µM KU55933), all cell lines showed similar kinetics of Rad51 foci. (**D**) WT, *AT* and both *Artemis* cell lines were seeded for colony formation, irradiated with 1, 2 or 4 Gy as indicated and incubated for 24 h in the presence or absence of 10 µM KU55933. Data without ATM inhibitor (black open symbols, dashed lines) were taken from [Figure 1](#gks604-F1){ref-type="fig"}. WT and both *Artemis* cell lines but not *AT* cells were sensitized by the ATM inhibitor KU55933 (black closed symbols). Co-treatment with 5 µM aphidicolin (gray closed symbols) partially relieved this sensitization.

Different residual Rad51 foci numbers were seen in *AT* and *Artemis* cells only after they had traveled through the S-phase before being arrested in G2 ([Figure 2](#gks604-F2){ref-type="fig"}B). Thus, we sought to elucidate whether Rad51 foci preferably appear during replication. Cells were EdU-labeled for 30 min before irradiation and nuclear Rad51 signals subsequently determined in those S-phase cells ([Supplementary Figure 4A](http://nar.oxfordjournals.org/cgi/content/full/gks604/DC1)). Discrete foci were clearly detectable after 1 h reaching in *WT* and FO2-385 and CJ179 *Artemis* cells a maximum number at 2 h (11.1, 9.9 and 9.1 foci, respectively) ([Figure 4](#gks604-F4){ref-type="fig"}B and [Supplementary Figure 4A](http://nar.oxfordjournals.org/cgi/content/full/gks604/DC1)) and declined thereafter presumably again due to successful repair. Notably, the concordant Rad51 kinetics of WT and *Artemis* cells strongly suggest that Artemis is not required for HR during the S-phase.

Surprisingly, in *AT* cells the number of Rad51 foci constantly increased over the whole time period reaching 9.6 foci at 6 h ([Figure 4](#gks604-F4){ref-type="fig"}B and [Supplementary Figure 4A](http://nar.oxfordjournals.org/cgi/content/full/gks604/DC1)). This amount of foci is well comparable to the foci numbers that were recorded 24 h after IR ([Figure 2](#gks604-F2){ref-type="fig"}B). Application of the ATM inhibitor KU55933 perfectly recapitulated the delayed but steadily increasing formation of Rad51 foci in all utilized cell lines during the S-phase ([Figure 4](#gks604-F4){ref-type="fig"}C and [Supplementary Figure 4B](http://nar.oxfordjournals.org/cgi/content/full/gks604/DC1)) as it was observed in *AT* cells without inhibitor. Moreover, in the presence of the ATM inhibitor, the fast increase and subsequent decline of Rad51 foci was abrogated in WT and *Artemis* cells indicating that HR during the S-phase is deficient in *AT* but not in *Artemis* cells. Consequently, we asked whether *Artemis* cells could be further sensitized by additional ATM inhibition and whether this preferably occurs in replicating cells. For this purpose, colony formation was measured in exponentially growing cultures. The ATM inhibitor decreased significantly the survival not only of WT but also of *Artemis* cells ([Figure 4](#gks604-F4){ref-type="fig"}D). To verify S-phase specificity, we temporarily blocked replication progress by additional treatment with aphidicolin for 6 h after IR, corresponding to the time frame in which *AT* cells accumulated most Rad51 foci ([Figure 4](#gks604-F4){ref-type="fig"}B). Strikingly, the radiosensitization through ATM inhibition was largely abrogated in WT and *Artemis* cells when replication was blocked (FO2-385 \> CJ179) ([Figure 4](#gks604-F4){ref-type="fig"}D). Accordingly, aphidicolin-treated *AT* cells also showed a moderate increase in cell survival. Together, these results indicate that HR processes during the S-phase strongly rely on ATM and that the particular deficiency during replication significantly contributes to the radiosensitive AT phenotype.

In the absence of ATM Rad51 focus formation requires functional ATR
-------------------------------------------------------------------

Recruitment of Rad51 to DSBs requires resection of DNA ends to generate RPA coated 3′-single-stranded overhangs. The resection process and hence the Rad51 focus formation was shown to be ATM-dependent ([@gks604-B33; @gks604-B34; @gks604-B35]) and may well explain that *AT* cells fail to accumulate Rad51 early after IR. However, the delayed but substantial generation of foci ([Figure 4](#gks604-F4){ref-type="fig"}B) must rely on other factors. Irradiation during the S-phase induces DSBs either directly or indirectly through collision of replication forks with single-strand breaks (SSBs) leading to 'one-ended' DSBs. During repair after IR both types of DSBs co-exist and cannot be systematically distinguished. However, the slowly and steadily increasing number of Rad51 foci in *AT* cells ([Figure 4](#gks604-F4){ref-type="fig"}B) may represent indirect DSBs accumulated during ongoing replication (i.e. RDS, see above ([@gks604-B7],[@gks604-B8])). To test whether this Rad51 accumulation is ATR-dependent---reminiscent of damage processing after UV-irradiation ([@gks604-B36],[@gks604-B37])---we treated EdU-labeled *AT* cells with 10 mM caffeine ([@gks604-B38]) and stained for Rad51 6 h after IR. In fact, caffeine treatment greatly diminished Rad51 focus formation to only background levels ([Figure 5](#gks604-F5){ref-type="fig"}A, and [Supplementary Figure 5A](http://nar.oxfordjournals.org/cgi/content/full/gks604/DC1) and [B](http://nar.oxfordjournals.org/cgi/content/full/gks604/DC1)). Caffeine, inhibiting both the ATR and ATM kinase ([@gks604-B38]), also widely reduced Rad51 focus formation in WT cells at 2 and 6 h after IR ([Figure 5](#gks604-F5){ref-type="fig"}A and [Supplementary Figure 5A](http://nar.oxfordjournals.org/cgi/content/full/gks604/DC1) and [B](http://nar.oxfordjournals.org/cgi/content/full/gks604/DC1)). To more specifically confirm that ATR is the major kinase required for Rad51 focus formation in ATM-impaired cells ([@gks604-B34],[@gks604-B39]), we treated CV-1 cells with the ATM-specific inhibitor KU55933 and additionally depleted ATR by siRNA ([Figure 5](#gks604-F5){ref-type="fig"}C). As expected, ATM inhibition alone slowly increased the number of radiation-induced Rad51 foci upon progression through the S-phase ([Figure 5](#gks604-F5){ref-type="fig"}B, scr + ATMi between 1 and 4 h). Depletion of the ATR kinase alone reduced Rad51 foci to half the amount observed in mock-depleted cells ([Figure 5](#gks604-F5){ref-type="fig"}B, i.e. 1 h after IR: light gray bar, 8.8 ± 1.2, versus dark gray bar, 21 ± 2.2 foci per cell). However, combined ATM inhibition and ATR depletion completely abolished Rad51 focus formation, well in line with the results after caffeine treatment ([Figure 5](#gks604-F5){ref-type="fig"}A). Notably, the combined function of ATM and ATR for Rad51 focus formation during the S-phase and its inhibition by caffeine was also previously observed after thymidine-induced replication stress ([@gks604-B40]). Figure 5.Rad51 focus formation in *AT* cells depends on functional ATR. (**A**) WT and *AT* cells were pre-treated with 10 mM caffeine for 2 h and pulse-labeled with EdU shortly before IR (1 Gy). Rad51 foci were recorded 2 and 6 h later in EdU-positive cells. Not only the foci number declined upon caffeine treatment but also the size of the remaining foci was reduced (see also [Supplementary Figure 5](http://nar.oxfordjournals.org/cgi/content/full/gks604/DC1)). (**B**) Quantification of Rad51 foci in EdU-positive CV-1 cells treated with ATR siRNA (**C**) and scrambled control without ATM inhibition (10 µM KU55933). (**D**) Western blot of Chk1 expressed in WT and *AT* cells irradiated with 10 Gy. (**E**) WT and *AT* cells were EdU-labeled, irradiated with 1 Gy and during repair continuously exposed to the Chk1 inhibitor UCN-01 (0.1 µM). Quantification of Rad51 foci 2 and 6 h after IR in EdU-positive cells.

ATR is the major kinase for Chk1 activation, an effector kinase, which is a critical component of the intra-S checkpoint and possibly implicated in Rad51 focus formation ([@gks604-B41]). Thus, we biochemically monitored the activation of Chk1 in both WT and *AT* cells ([Figure 5](#gks604-F5){ref-type="fig"}D). *AT* cells displayed a late phospho-Chk1 signal, most intense at 4--6 h after IR, in parallel with the delayed formation of Rad51 foci. WT cells showed a much weaker signal with the most intense band at 1--2 h after IR, again consistent with the Rad51 focus peak of this cell line ([Figure 4](#gks604-F4){ref-type="fig"}A and B). To more directly test whether Chk1 is involved in Rad51 focus formation during the S-phase, we inhibited Chk1 by using the specific inhibitor UCN-01 ([@gks604-B41]). Following Chk1 inhibition, EdU-positive WT and *AT* cells showed a reduced number of Rad51 foci ([Figure 5](#gks604-F5){ref-type="fig"}E), indicating that not only ATR but also Chk1 is involved in Rad51 focus formation.

Taken together, during the S-phase ATR and its effector kinase Chk1 are partly required for Rad51 focus formation in ATM-proficient cells but essential in the absence of ATM. However, functional ATR and Chk1 alone appear not to be sufficient for successful repair of IR-induced DSBs during the S-phase because no decline of Rad51 foci was observed in ATM-deficient cells ([Figure 4](#gks604-F4){ref-type="fig"}B and C). The enhanced Rad51 focus number in G2-phase *AT* cells 24 h after IR ([Figure 2](#gks604-F2){ref-type="fig"}B) strongly suggests that the repair of DSBs that arose during the replicative S-phase cannot be completed in the subsequent G2-phase.

DISCUSSION
==========

Both ATM and Artemis were shown to be equally required for NHEJ repair of a subset of IR-induced DSBs in both the G1- and G2-phase ([@gks604-B5],[@gks604-B12],[@gks604-B20]). ATM is also known to be involved in HR ([@gks604-B21; @gks604-B22; @gks604-B23; @gks604-B24; @gks604-B25]) and recently *Artemis* cells were shown to display a similar HR defect after IR in the G2-phase ([@gks604-B20]) (and this study [Figure 4](#gks604-F4){ref-type="fig"}A) The remarkably diverse repair phenotype reported here demonstrates that ATM but not Artemis is essential for HR during the S-phase ([Figure 4](#gks604-F4){ref-type="fig"}B--D). We thus conclude that the *AT* and *Artemis* repair defects are widely epistatic in G1- and G2- but not in the S-phase.

*AT* cells irradiated in S-phase accumulate numerous Rad51 foci gradually, which could be blocked when ATR or Chk1 are additionally inhibited. The radiation-induced Rad51 focus formation in *AT* cells was unexpected because ATM is known to be required for the resection of 5′-DNA ends ([@gks604-B33; @gks604-B34; @gks604-B35],[@gks604-B42],[@gks604-B43]). The free 3′-ss-tails are rapidly coated by RPA, which is the substrate for subsequent chromatin loading of Rad51 ([@gks604-B31]). ATM presumably activates through phosphorylation several essential components of the resection process, such as the MRN complex, CtIP, BRCA1, WRN, BLM and EXO1 ([@gks604-B44; @gks604-B45; @gks604-B46; @gks604-B47; @gks604-B48; @gks604-B49; @gks604-B50; @gks604-B51]). However, ATM's precise role for the resection process and for subsequent recombination steps is not clear yet. In the absence of ATM, the related kinase ATR might phosphorylate several of the latter proteins with delayed kinetics ([@gks604-B50],[@gks604-B52]). However, activation of ATR requires the presence of RPA-coated ssDNA and accordingly is considered to be a downstream event in ATM activation ([@gks604-B43],[@gks604-B53],[@gks604-B54]). Two explanations may reconcile these apparent contradictions. (i) A yet unknown ATM-independent resection step precedes the ATR activation. (ii) Resection is not required because the replicative MCM2-7 helicase complex may progress beyond an IR-induced SSB (i.e. when located on the lagging strand), exposing sufficient ssDNA to activate ATR--ATRIP and subsequent Rad51 loading. This scenario might perfectly recapitulate the signalling and processing of UV damage ([@gks604-B36],[@gks604-B37],[@gks604-B55; @gks604-B56; @gks604-B57]). In addition, MCM2-7 is a regular phosphorylation target of ATM ([@gks604-B44]) and ATM-catalyzed phosphorylation possibly inhibits the helicase's activity, promoting the generation of ssDNA after DNA damage. Thus, cells lacking ATM might then expose particularly long ssDNA stretches, thereby facilitating loading of RPA and subsequently activation of ATR. The possibility that ATR is activated without preceding resection does not exclude that HR of replication-associated DSB implicates delayed secondary resection, i.e. by EXO1 ([@gks604-B50]).

How might ATR control Rad51 focus formation? Beside its hypothesized function in delayed end resection ([@gks604-B50]), ATR is the principal kinase that activates Chk1, which in turn phosphorylates Rad51 at T309. This phosphorylation step has been shown to be essential for Rad51 focus formation and HR after replication stress ([@gks604-B41]). In addition, chromatin loading of Rad51 requires c-Abl-mediated phosphorylation at Y54 and Y315 ([@gks604-B58]) and damage-induced activation of c-Abl is known to be ATM-dependent ([@gks604-B44],[@gks604-B59],[@gks604-B60]). Hence, it is tempting to speculate that ATR can take over in *AT* cells particularly during the S-phase, which has hitherto not been demonstrated because only asynchronous cell populations were investigated ([@gks604-B59]).

Although recruitment of Rad51 in *AT* cells leads to visible foci, its kinetics are significantly delayed during the S- and G2-phase ([Figure 4](#gks604-F4){ref-type="fig"}A and B ([@gks604-B61])). This delay might result from both insufficient DNA end resection and/or insufficient H2AX phosphorylation ([@gks604-B62]), which is known to be a prerequisite for timely Rad51 accumulation at sites of DNA damage ([@gks604-B63; @gks604-B64; @gks604-B65]). Despite successful recruitment of Rad51 to finally all unrejoined DSBs, HR appears to be widely inhibited in cells lacking functional ATM as (i) the number of IR-induced Rad51 foci never declined during the S- or G2-phase and (ii) gene conversion efficiency of I-SceI-generated DSBs was strongly reduced. Recently, it was shown that the ATM defect in G2 is restricted to HR of DSBs induced in heterochromatic regions ([@gks604-B20]), similar to NHEJ in G1 ([@gks604-B18],[@gks604-B19]). Notably, neither I-SceI cleavage nor the majority of replication-associated DSBs likely occur in heterochromatin. Thus, we suggest that ATM has more universal but still not precisely defined functions in HR. In addition to end resection and relaxation of heterochromatin, ATM emerges as being more generally involved in chromatin remodeling through activation of RNF20 and 40 ([@gks604-B66]), as well as in damage-induced sister chromatid cohesion, presumably through activation of the cohesin component SMC1 ([@gks604-B67; @gks604-B68; @gks604-B69]), which facilitates homology search and strand exchange. Moreover, the accessory factors XRCC2 and 3 are also ATM phosphorylation targets ([@gks604-B44]), of which at least XRCC3 is involved in branch migration and perhaps resolution of the putative Holliday structure ([@gks604-B70],[@gks604-B71]), two other steps downstream of Rad51 loading.

Artemis---and particularly its nuclease function ([@gks604-B20])---is required for efficient DSB repair (γH2AX foci) in general and Rad51 focus formation in the G2-phase ([Figures 1](#gks604-F1){ref-type="fig"}, [2](#gks604-F2){ref-type="fig"}, and [4](#gks604-F4){ref-type="fig"}). However, we show here that Artemis is dispensable for HR during the S-phase, which is clearly different from ATM. Two explanations can be advanced. The end resection process is modulated by CDKs of which CDK2 activity peaks during S-phase ([@gks604-B47],[@gks604-B49],[@gks604-B72]). This kinase activity thus stimulates the MRN/CtIP-mediated resection during replication to an extend where it might not depend upon supportive Artemis nuclease---in contrast to the slower and less extensive end degradation in G2 ([@gks604-B73]) where Artemis is always required. An alternative explanation for Artemis being dispensable in S-phase is the relaxed DNA structure, which may also facilitate end processing independent of the specific Artemis activity.

Based on our observation that Artemis depletion reduced the gene conversion rate in the chromosomal I-SceI-based reporter construct ([Figure 3](#gks604-F3){ref-type="fig"}C), we propose that Artemis, similar to ATM, has HR function beyond the repair of only heterochromatic lesions. However, ATM appears to play a more pivotal role in HR ([Figure 3](#gks604-F3){ref-type="fig"}C) because cell survival of Artemis-deficient cells could be further compromised by ATM inhibition ([Figure 4](#gks604-F4){ref-type="fig"}D). Artemis-deficient cells have now in addition lost the G1/S checkpoint and fail to execute HR repair of direct and indirect DSBs during the S-phase. However, this additional toxicity of ATM inhibition was widely relieved when replication was temporarily blocked ([Figure 4](#gks604-F4){ref-type="fig"}D).

In conclusion, we show that both radiosensitivity syndromes, AT and Artemis, are linked to DSB repair deficiencies affecting NHEJ and HR. The repair phenotypes are similar in the G1- and G2-phase but not fully epistatic. Importantly, only *AT* but not *Artemis* cells display an additional HR defect in S-phase. Lack of functional ATM affects repair of direct and indirect replication-associated DSBs, leading to enhanced numbers of unresolved recombination foci in G2 as corroborated by persisting Rad51 foci and a more prominent G2-arrest than it is the case for *Artemis* or WT cells.

SUPPLEMENTARY DATA
==================

[Supplementary Data](http://nar.oxfordjournals.org/cgi/content/full/gks604/DC1) are available at NAR Online: Supplementary Figures 1--5.

FUNDING
=======

S.K. is supported by a grant from the German Federal Ministry of Education and Research \[BMBF 02NUK001D to J.D.D.\]; T.R. and G.R. are supported by a grant of the German Cancer Aid \[Deutsche Krebshilfe 107889 to J.D.D. and 107980 to I.D.\] and the German Federal Ministry of Environmental Protection \[Bundesamt für Strahlenschutz 3610530016 to J.DD. and I.D.\]. Funding for open access charge: Institutional.

*Conflict of interest statement*. None declared.

Supplementary Material
======================

###### Supplementary Data

The authors thank M. Kriegs and K. Dreffke for critical reading of this article.
